BiochemProbe — Life Science Research Reagents

Alogabat free base

Alogabat is a positive allosteric modulator and agonist of the GABAA α5 receptor.

For research use only. Not for human or veterinary use.

Target GABA Receptor
Research area Neurological Disease
Purity >98% Stock Inquire

Alogabat structure

CAS No.: 2230009-48-8

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
100 mg USD 698.00 BP-00042-100mg In stock Get quote
250 mg USD 1,198.00 BP-00042-250mg In stock Get quote
500 mg USD 1,988.00 BP-00042-500mg In stock Get quote
1 g USD 2,580.00 BP-00042-1g In stock Get quote
2 g Inquire BP-00042-2g In stock Inquire

Need another size or custom synthesis? Request a quote.

Description

Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction.

Biological activity

In Vitro Alogabat (compound 8) binds selectively to the α5 subunit over α1, α2, and α3. The Ki in HEK293 cells is 8.7 nM (hGABA-Aα5β3γ2). Alogabat (30×Ki=261 nM, transient) potently enhances GABA-evoked currents in oocytes with an efficiency of 97% to elicit 20% of the maximal current response (EC20).

Identifiers

SMILES
O=C(NC1CCOCC1)C2=NN=C(OCC=3C(=NOC3C)C=4C=NC(=CC4)C)C=C2
InChIKey
ACZCJTHHWMBFKC-UHFFFAOYSA-N

Specifications

MW (average)
409.4384
Formula
C21H23N5O4
CAS No.
2230009-48-8
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20°C, 3 years , 4°C, 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro
DMSO : 33.33 mg/mL

References

[1]. Bernd Buettelmann, et al. Preparation of new isoxazolyl ether derivatives as GABAA α5 receptor positive allosteric modulators (PAMs). World Intellectual Property Organization, WO2018104419 A1 2018-06-14.
[2]. Belew Mekonnen, et al. Benzazepine derivatives for the treatment of cognitive impairment and their preparation. World Intellectual Property Organization, WO2024039886 A1 2024-02-22.

Same target

Search GABA Receptor

Same research area

Search Neurological Disease